Encouraging the Development of New Antibiotics: Are Financial Incentives the Right Way Forward? A Systematic Review and Case Study

References

• Sinha MS, Kesselheim AS. Regulatory incentives for antibiotic drug development: a review of recent proposals. Bioorg Med Chem. 2016;24(24):6446–6451. doi:10.1016/j.bmc.2016.08.03327591793
   PubMed Web of Science ®Google Scholar
• Office of National Statistics. Causes of death over 100 years. 2017 Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/articles/causesofdeathover100years/2017-09-18. Accessed 410, 2020.
   Google Scholar
• Jones DS, Podolsky SH, Greene JA. The burden of disease and the changing task of medicine. N Engl J Med. 2012;366(25):2333–2338. doi:10.1056/NEJMp111356922716973
   PubMed Web of Science ®Google Scholar
• Podolsky SH. The evolving response to antibiotic resistance (1945–2018). Palgrave Commun. 2018;4:1. doi:10.1057/s41599-018-0181-x
   Web of Science ®Google Scholar
• Aslam B, Wang W, Arshad MI, et al. Antibiotic resistance: a rundown of a global crisis. Infect Drug Resist. 2018;11:1645–1658. doi:10.2147/IDR.S17386730349322
   PubMed Web of Science ®Google Scholar
• O’Neill J. Tackling drug-resistant infections globally: final report and recommendations. 2016 Available from: https://amr-review.org/. Accessed 410, 2020.
   Google Scholar
• Baraka MA, Alsultan H, Alsalman T, Alaithan H, Islam MA, Alasseri AA. Health care providers’ perceptions regarding antimicrobial stewardship programs (AMS) implementation—facilitators and challenges: a cross-sectional study in the Eastern province of Saudi Arabia. Ann Clin Microbiol Antimicrob. 2019;18(1):26. doi:10.1186/s12941-019-0325-x31551088
   PubMed Web of Science ®Google Scholar
• Bianco A, Papadopoli R, Mascaro V, Pileggi C, Pavia M. Antibiotic prescriptions to adults with acute respiratory tract infections by Italian general practitioners. Infect Drug Resist. 2018;11:2199–2205. doi:10.2147/IDR.S17034930519057
   PubMed Web of Science ®Google Scholar
• Council of Canadian Academies. When antibiotics fail. 2019 Available from: https://cca-reports.ca/wp-content/uploads/2018/10/When-Antibiotics-Fail-1.pdf. Accessed 49, 2020.
   Google Scholar
• Dekker ARJ, Verheij TJM, Van Der Velden AW. Inappropriate antibiotic prescription for respiratory tract indications: most prominent in adult patients. Fam Pract. 2015;32(4):401–407. doi:10.1093/fampra/cmv01925911505
   PubMed Web of Science ®Google Scholar
• Knight GM, McQuaid CF, Dodd PJ, Houben RMGJ. Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling. Lancet Infect Dis. 2019;19(8):903–912. doi:10.1016/S1473-3099(19)30307-X31281059
   PubMed Web of Science ®Google Scholar
• Abelenda-Alonso G, Padullés A, Rombauts A, et al. Antibiotic prescription during the COVID-19 pandemic: a biphasic pattern. Infect Control Hosp Epidemiol. 2020;41(11):1371–1372. doi:10.1017/ice.2020.38132729437
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global action plan on antimicrobial resistance. 2015 Available from: https://www.who.int/antimicrobial-resistance/global-action-plan/en/. Accessed 314, 2020.
   Google Scholar
• Government of Canada. Tackling antimicrobial resistance and antimicrobial use: a pan-Canadian framework for action. 2017 Available from: https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/tackling-antimicrobial-resistance-use-pan-canadian-framework-action.html. Accessed 49, 2020.
   Google Scholar
• Sabtu N, Enoch DA, Brown NM. Antibiotic resistance: what, why, where, when and how? Br Med Bull. 2015;116(1):105–113. doi:10.1093/bmb/ldv04126491083
   PubMed Web of Science ®Google Scholar
• World Health Organization. 2019 antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline. 2019 Available from: https://www.who.int/publications/i/item/9789240000193. Accessed 415, 2020.
   Google Scholar
• Outterson K, Powers JH, Daniel GW, McClellan MB. Repairing the broken market for antibiotic innovation. Health Aff. 2015;34(2):277–285. doi:10.1377/hlthaff.2014.1003
   Web of Science ®Google Scholar
• Renwick M, Brogan DM, Mossialos E. A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics. J Antibiot (Tokyo). 2016;69(2):73–88. doi:10.1038/ja.2015.9826464014
   PubMed Web of Science ®Google Scholar
• Batista H, Byrski D, Lamping M, Romandini R. IP-based incentives against antimicrobial crisis: a European perspective. Int Rev Intellect Prop Compet Law. 2019;50:30–76. doi:10.1007/s40319-018-00782-w
   Web of Science ®Google Scholar
• Talbot GH, Jezek A, Murray BE, et al. The infectious diseases society of America’s 10 × ’20 initiative (10 new systemic antibacterial agents US Food and Drug Administration approved by 2020): is 20 × ’20 a possibility? Clin Infect Dis. 2019;69(1):1–11. doi:10.1093/cid/ciz08930715222
   PubMed Web of Science ®Google Scholar
• Renwick M, Mossialos E. What are the economic barriers of antibiotic R&D and how can we overcome them? Expert Opin Drug Discov. 2018;13(10):889–892. doi:10.1080/17460441.2018.151590830175625
   PubMed Web of Science ®Google Scholar
• Brogan DM, Mossialos E. Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model. Global Health. 2013;9(58):1–10. doi:10.1186/1744-8603-9-5823327564
   PubMed Web of Science ®Google Scholar
• Darrow J, Sinha M, Kesselheim A. When markets fail: patents and infectious disease products. Food Drug Law J. 2018;73(3):361–382. doi:10.2307/26661184
   Web of Science ®Google Scholar
• Chit A, Grootendorst P. Policy to encourage the development of antimicrobials. Int J Health Gov. 2018;23(2):101–110. doi:10.1108/IJHG-12-2017-0062
   Web of Science ®Google Scholar
• Hollis A, Maybarduk P. Antibiotic resistance is a tragedy of the commons that necessitates global cooperation. J Law Med Ethics. 2015;43:33–37. doi:10.1111/jlme.12272
   PubMed Web of Science ®Google Scholar
• Anderson M, Clift C, Schulze K, et al. Averting the AMR crisis: what are the avenues for policy action for countries in Europe? 2019 Available from: https://www.oecd.org/health/health-systems/Averting-the-AMR-crisis-Policy-Brief-32-March-2019.PDF. Accessed 410, 2020.
   Google Scholar
• Klein EY, Van Boeckel TP, Martinez EM, et al. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad Sci U S A. 2018;115(15):E3463–E3470. doi:10.1073/pnas.171729511529581252
   PubMed Web of Science ®Google Scholar
• Årdal C, Røttingen J-A, Opalska A, Van Hengel AJ, Larsen J. Pull incentives for antibacterial drug development: an analysis by the transatlantic task force on antimicrobial resistance. Clin Infect Dis. 2017;65(8):1378–1382. doi:10.1093/cid/cix52629017240
   PubMed Web of Science ®Google Scholar
• Luepke KH, Suda KJ, Boucher H, et al. Past, present, and future of antibacterial economics: increasing bacterial resistance, limited antibiotic pipeline, and societal implications. Pharmacotherapy. 2017;37(1):71–84. doi:10.1002/phar.186827859453
   PubMed Web of Science ®Google Scholar
• Finland M, Kirby W, Chabbert Y, et al. Round table: are new antibiotics needed? Antimicrob Agents Chemother. 1965;5:1107–1114.5883409
   PubMedGoogle Scholar
• Ciabuschi F, Baraldi E, Lindahl O, Callegari S. Supporting innovation against the threat of antibiotic resistance: exploring the impact of public incentives on firm performance and entrepreneurial orientation. J Bus Res. 2019;112:271–280. doi:10.1016/j.jbusres.2019.12.021
   Web of Science ®Google Scholar
• So AD, Shah TA. New business models for antibiotic innovation. Ups J Med Sci. 2014;119(2):176–180. doi:10.3109/03009734.2014.89871724646116
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.100009719621072
   PubMed Web of Science ®Google Scholar
• Baraldi E, Ciabuschi F, Leach R, Morel C, Waluszewski A. Exploring the obstacles to implementing economic mechanisms to stimulate antibiotic research and development: a multi-actor and system-level analysis. Am J Law Med. 2016;42(2–3):451–486. doi:10.1177/009885881665827629086643
   PubMed Web of Science ®Google Scholar
• Savic M, Årdal C. A grant framework as a push incentive to stimulate research and development of new antibiotics. J Law Med Ethics. 2018;46:9–24. doi:10.1177/107311051878291130146963
   PubMed Web of Science ®Google Scholar
• Brogan DM, Mossialos E. Systems, not pills: the options market for antibiotics seeks to rejuvenate the antibiotic pipeline. Soc Sci Med. 2016;151:167–172. doi:10.1016/j.socscimed.2016.01.00526808335
   PubMed Web of Science ®Google Scholar
• Sciarretta K, Røttingen J-A, Opalska A, Van Hengel AJ, Larsen J. Economic incentives for antibacterial drug development: literature review and considerations from the transatlantic task force on antimicrobial resistance. Clin Infect Dis. 2016;63(11):1470–1474. doi:10.1093/cid/ciw59327578820
   PubMed Web of Science ®Google Scholar
• Morel C, Edwards SE. Encouraging sustainable use of antibiotics: a commentary on the DRIVE-AB recommended innovation incentives. J Law Med Ethics. 2018;46:75–80. doi:10.1177/107311051878291830146962
   PubMed Web of Science ®Google Scholar
• Daniel GW, Schneider M, Lopez MH, McClellan MB. Implementation of a market entry reward within the United States. J Law Med Ethics. 2018;46:50–58. doi:10.1177/107311051878291530146957
   PubMed Web of Science ®Google Scholar
• Hojgard S. Antibiotic resistance - why is the problem so difficult to solve? Infect Ecol Epidemiol. 2012;2(1):1–7. doi:10.3402/iee.v2i0.18165
   Google Scholar
• Kesselheim AS, Outterson K. Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals. Health Aff. 2010;29(9):1689–1696. doi:10.1377/hlthaff.2009.0439
   PubMed Web of Science ®Google Scholar
• Kesselheim AS, Outterson K. Improving antibiotic markets for long-term sustainability. Yale J Health Policy Law Ethics. 2011;11(1):101–167.21381513
   PubMedGoogle Scholar
• Laxminarayan R, Powers JH. Antibacterial R&D incentives. Nat Rev Drug Discov. 2011;10(10):727–728. doi:10.1038/nrd356021959280
   PubMed Web of Science ®Google Scholar
• Mckellar MR, Fendrick AM. Innovation of novel antibiotics: an economic perspective. Clin Infect Dis. 2014;59(suppl_3):S104–S107. doi:10.1093/cid/ciu53025261536
   PubMed Web of Science ®Google Scholar
• Okhravi C, Callegari S, McKeever S, et al. Simulating market entry rewards for antibiotics development. J Law Med Ethics. 2018;46:32–42. doi:10.1177/107311051878291330146961
   PubMed Web of Science ®Google Scholar
• Simpkin VL, Renwick MJ, Kelly R, Mossialos E. Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps. J Antibiot (Tokyo). 2017;70(12):1087–1096. doi:10.1038/ja.2017.12429089600
   PubMed Web of Science ®Google Scholar
• Towse A, Hoyle CK, Goodall J, Hirsch M, Mestre-Ferrandiz J, Rex JH. Time for a change in how new antibiotics are reimbursed: development of an insurance framework for funding new antibiotics based on a policy of risk mitigation. Health Policy (New York). 2017;121(10):1025–1030. doi:10.1016/j.healthpol.2017.07.011
   PubMed Web of Science ®Google Scholar
• Towse A, Sharma P. Incentives for R&D for new antimicrobial drugs. Int J Econ Bus. 2011;18(2):331–350. doi:10.1080/13571516.2011.584434
   Google Scholar
• Årdal C, Johnsen J, Johansen K. Designing a delinked incentive for critical antibiotics: lessons from Norway. J Law Med Ethics. 2018;46:43–49. doi:10.1177/107311051878291430146956
   PubMed Web of Science ®Google Scholar
• Daniel GW, Schneider M, McClellan MB. Addressing antimicrobial resistance and stewardship: the Priority Antimicrobial Value and Entry (PAVE) award. JAMA. 2017;318(12):1103–1104. doi:10.1001/jama.2017.1016428772301
   PubMed Web of Science ®Google Scholar
• Bhatti T, Lum K, Holland S, Sassman S, Findlay D, Outterson K. A perspective on incentives for novel inpatient antibiotics: no one-size-fits-all. J Law Med Ethics. 2018;46:59–65. doi:10.1177/107311051878291630146959
   PubMed Web of Science ®Google Scholar
• Brogan DM, Mossialos E. A critical analysis of the review on antimicrobial resistance report and the infectious disease financing facility. Global Health. 2016;12(8). doi:10.1186/s12992-016-0147-y
   Web of Science ®Google Scholar
• Livermore DM. The 2018 Garrod lecture: preparing for the black swans of resistance. J Antimicrob Chemother. 2018;73(11):2907–2915. doi:10.1093/jac/dky26530351434
   PubMed Web of Science ®Google Scholar
• Lum K, Bhatti T, Holland S, Guthrie M, Sassman S. Diagnosis confirmation model: a value-based pricing model for inpatient novel antibiotics. J Law Med Ethics. 2018;46(1_suppl):66–74. doi:10.1177/107311051878291730146960
   PubMed Web of Science ®Google Scholar
• Outterson K, Rex JH. Evaluating for-profit public benefit corporations as an additional structure for antibiotic development and commercialization. Transl Res. 2020;220:182–190. doi:10.1016/j.trsl.2020.02.00632165059
   PubMed Web of Science ®Google Scholar
• Rex JH, Outterson K. Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach. Lancet Infect Dis. 2016;16(4):500–505. doi:10.1016/S1473-3099(15)00500-927036356
   PubMed Web of Science ®Google Scholar
• Singer AC, Kirchhelle C, Roberts AP. Reinventing the antimicrobial pipeline in response to the global crisis of antimicrobial-resistant infections. F1000Research. 2019;8:238. doi:10.12688/f1000research.18302.130906539
   PubMedGoogle Scholar
• Spellberg B. The future of antibiotics. Crit Care. 2014;18(3):228. doi:10.1186/cc1394825043962
   PubMed Web of Science ®Google Scholar
• Theuretzbacher U, Årdal C, Harbarth S. Linking sustainable use policies to novel economic incentives to stimulate antibiotic research and development. Infect Dis Rep. 2017;9(1):28–31. doi:10.4081/idr.2017.6836
   Google Scholar
• Vågsholm I, Höjgård S. Antimicrobial sensitivity: a natural resource to be protected by a pigouvian tax? Prev Vet Med. 2010;96:9–18. doi:10.1016/j.prevetmed.2010.05.00320570379
   PubMed Web of Science ®Google Scholar
• Rome BN, Kesselheim AS. Transferrable market exclusivity extensions to promote antibiotic development: an economic analysis. Clin Infect Dis. 2019. doi:10.1093/cid/ciz1039
   Web of Science ®Google Scholar
• James JE. Can public financing of the private sector defeat antimicrobial resistance? J Public Health. 2018;41(2):422–426. doi:10.1093/pubmed/fdy116
   Web of Science ®Google Scholar
• The Chatham House. Towards a new global business model for antibiotics: delinking revenues from sales. 2015 Available from: https://www.chathamhouse.org/sites/default/files/field/field_document/20151009NewBusinessModelAntibioticsCliftGopinathanMorelOuttersonRottingenSo.pdf. Accessed 122, 2020.
   Google Scholar
• Babic M, Heemskerk E, Fichtner J. Who is more powerful – states or corporations? Conversation. 2018.
   Google Scholar
• Rubin IS. The politics of public budgets In: Rubin IS, ed. The Politics of Public Budgeting: Getting and Spending, Borrowing and Balancing. CQ Press; 2016:1–37.
   Google Scholar
• Grace C, Kyle M. Comparative advantages of push and pull incentives for technology development: lessons for neglected disease technology development. 2009:147–151. Available from: http://www.margaretkyle.net/PushPull.pdf. Accessed 12, 2021.
   Google Scholar
• Renwick MJ, Simpkin V, Mossialos E, Schippers E. Targeting innovation in antibiotic drug discovery and development. 2016 Available from: https://www.euro.who.int/__data/assets/pdf_file/0003/315309/Targeting-innovation-antibiotic-drug-d-and-d-2016.pdf. Accessed 49, 2020.
   Google Scholar
• Shlaes DM. The economic conundrum for antibacterial drugs. Antimicrob Agents Chemother. 2020;64(1):1–7. doi:10.1128/AAC.02057-19
   Web of Science ®Google Scholar
• National Institute for Health and Care Excellence, National Health Service. Developing and testing innovative models for the evaluation and purchase of antimicrobials: subscription-based payment model. 2020 Available from: https://amr.solutions/wp-content/uploads/2020/03/2020-03-25-NHS-AMR-Market-Engagement-Briefing-Final.pdf. Accessed 126, 2020.
   Google Scholar
• Public Health Agency of Sweden. Folkhälsomyndigheten utvärderar ny ersättningsmodell för viktiga antibiotika. 2019 Available from: https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2019/juni/folkhalsomyndigheten-utvarderar-ny-ersattningsmodell-for-viktiga-antibiotika/. Accessed 126, 2020.
   Google Scholar
• Public Health Agency of Sweden. Analys Av Förutsättningar För Att Testa En Ny Ersättningsmodell För Antibiotika. 2016 Available from: https://www.folkhalsomyndigheten.se/publicerat-material/publikationsarkiv/a/analys-av-forutsattningar-for-att-testa-en-ny-ersattningsmodell-for-antibiotika/. Accessed 126, 2020.
   Google Scholar
• Rex JH. Sweden to test an access-focused model for new antibiotics: contracting for availability. 2020 Available from: https://amr.solutions/2020/03/16/sweden-to-test-an-access-focused-model-for-new-antibiotics-contracting-for-availability/. Accessed 126, 2020.
   Google Scholar
• Government of Canada. Canada’s health care system. 2016 Available from: https://www.canada.ca/en/health-canada/services/canada-health-care-system.html. Accessed 1010, 2020.
   Google Scholar
• Government of Canada. A prescription for Canada: achieving pharmacare for all. 2019 Available from: https://www.canada.ca/en/health-canada/corporate/about-health-canada/public-engagement/external-advisory-bodies/implementation-national-pharmacare/final-report.html. Accessed 1010, 2020.
   Google Scholar
• Public Health Agency of Canada. Canadian antimicrobial resistance surveillance system report. 2020 Available from: https://www.canada.ca/content/dam/hc-sc/documents/services/drugs-health-products/canadian-antimicrobial-resistance-surveillance-system-2020-report/CARSS-2020-report-2020-eng.pdf. Accessed 724, 2020.
   Google Scholar
• Government of Canada. About antibiotic resistance: preserving antibiotics now and in the future. 2019 Available from: https://www.canada.ca/en/public-health/corporate/publications/chief-public-health-officer-reports-state-public-health-canada/preserving-antibiotics/about-antibiotic-resistance.html. Accessed 1121, 2019
   Google Scholar
• Public Health Agency of Canada. Federal action plan on antimicrobial resistance and use in Canada. 2015 Available from: https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/federal-action-plan-antimicrobial-resistance-canada.html. Accessed 49, 2020.
   Google Scholar
• Government of Canada. Notice - health Canada’s efforts to support innovative human therapeutic products to combat antimicrobial resistance. 2018 Available from: https://www.canada.ca/en/health-canada/programs/consultation-proposed-pathogens-interest-list/notice-efforts-combat-antimicrobial-resistance.html. Accessed 1121, 2019.
   Google Scholar
• Government of Canada. Canada’s pharmaceutical industry and prospects. 2013 Available from: https://www.ic.gc.ca/eic/site/lsg-pdsv.nsf/eng/hn01768.html. Accessed 126, 2020.
   Google Scholar
• Government of Canada. Pharmaceutical industry profile. 2019 Available from: https://www.ic.gc.ca/eic/site/lsg-pdsv.nsf/eng/h_hn01703.html. Accessed 126, 2020.
   Google Scholar
• Sharma P, Towse A. New drugs to tackle antimicrobial resistance: analysis of EU policy options; 2010 Available from: https://www.ohe.org/publications/new-drugs-tackle-antimicrobial-resistance-eu-policy-options. Accessed 49, 2020.
   Google Scholar
• Rawson NSB. National pharmacare in Canada: equality or equity, accessibility or affordability. Int J Health Policy Manag. 2020;9(12):524–527. doi:10.15171/ijhpm.2019.14632610769
   PubMed Web of Science ®Google Scholar